Investor Relations

Investor Search

Entire IR Site
Press Releases Only
Filings Only
Email pagePDF viewPrint viewEmail AlertRSS FeedsTearsheetMobile IR SiteSocial Media Sharing

Press Releases


Display:

Year:
Notify me when new press releases are posted to this site .
Press Releases 
DateHeadlineFormat
3/01/2013Repligen to Report Fourth Quarter and Full Year 2012 Financial Results
1/03/2013Repligen Announces Licensing Agreement with Pfizer for Spinal Muscular Atrophy Program
11/08/2012Repligen Reports Third Quarter 2012 Financial Results
11/07/2012Repligen CEO to Present at Upcoming Investor Conferences
10/26/2012Repligen To Report Third Quarter of 2012 Financial Results
9/21/2012Repligen Appoints Jonathan I. Lieber as CFO
8/29/2012Repligen to Present at Stifel Nicolaus Healthcare Conference 2012
8/02/2012Repligen Announces Strategic Focus on Bioprocessing Business and Reports Second Quarter 2012 Financial Results
7/24/2012Repligen To Report Second Quarter of 2012 Financial Results
7/06/2012Repligen to Present at JMP Securities Healthcare Conference 2012
6/25/2012Repligen Added to the Russell 2000 Index
6/22/2012Repligen Receives Complete Response Letter from FDA for RG1068 NDA
5/30/2012Repligen to Present at Jefferies 2012 Global Healthcare Conference
5/07/2012Repligen Announces Support of Amended Stockholder Proposal
5/03/2012Repligen Reports First Quarter 2012 Financial Results
4/30/2012Repligen Announces Conference Call to Report First Quarter of 2012 Financial Results
4/26/2012Repligen Provides Regulatory Update for RG1068 New Drug Application; FDA Cancels Advisory Committee Meeting
4/25/2012Repligen Reports Positive Results from Phase 1 Clinical Trial of RG3039 for Spinal Muscular Atrophy
4/11/2012Michael A. Griffith Appointed to Repligen Board of Directors
3/23/2012Repligen Announces FDA Advisory Committee Date for SecreFlo™ NDA
Click the link to the right to download: Adobe Acrobat
 
 Source: SNL Financial LC
Rows 41 through 60 of 159 1 2 3 4 5 6 7 8

Copyright 2015, © SNL Financial LC  Terms of Use